Lansforsakringar Fondforvaltning AB publ Buys 5,202 Shares of Becton, Dickinson and Company $BDX

Lansforsakringar Fondforvaltning AB publ boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 93,128 shares of the medical instruments supplier’s stock after acquiring an additional 5,202 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Becton, Dickinson and Company were worth $17,431,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after acquiring an additional 147,041 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Becton, Dickinson and Company by 7.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock valued at $1,712,715,000 after acquiring an additional 636,138 shares during the last quarter. First Eagle Investment Management LLC raised its position in shares of Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after acquiring an additional 3,268,478 shares during the period. Geode Capital Management LLC boosted its stake in Becton, Dickinson and Company by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 6,723,702 shares of the medical instruments supplier’s stock worth $1,153,157,000 after acquiring an additional 244,199 shares during the last quarter. Finally, Norges Bank acquired a new position in Becton, Dickinson and Company during the second quarter valued at approximately $653,377,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Up 1.6%

Shares of BDX opened at $185.43 on Monday. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $185.50. The firm’s 50 day moving average is $197.33 and its 200-day moving average is $192.49. The stock has a market capitalization of $52.80 billion, a PE ratio of 30.25, a P/E/G ratio of 13.44 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several brokerages recently issued reports on BDX. Wells Fargo & Company decreased their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 10th. Piper Sandler reiterated a “neutral” rating and set a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Jefferies Financial Group cut their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, JPMorgan Chase & Co. reduced their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $195.46.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,416 shares of company stock valued at $675,557. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.